Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

A $3.2B takeout of partner Translate Bio tees Sanofi up to build out mRNA franchise

Year’s second-largest biotech buyout caps nearly 200% stock run sparked by COVID program 

By Jeff Cranmer, Executive Editor, AND Paul Bonanos, Associate Editor
August 3, 2021 5:04 AM UTC

After a three-year partnership that took on urgency as the COVID-19 pandemic widened, Sanofi has proposed to acquire partner Translate Bio for $3.2 billion.

Rumors of a pending deal sent shares of Translate Bio Inc. (NASDAQ:TBIO) up more than 70% to $50.35 in after-hours trading late Monday. Sanofi (Euronext:SAN; NASDAQ:SNY) announced the proposed deal several hours later, early Paris time on Tuesday...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Jazz Pharmaceuticals plc

Sanofi

Translate Bio Inc.